{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-070134","form_type":"8-K","ticker":"BJDX","cik":"0001704287","company_name":"Bluejay Diagnostics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.766450+00:00","generated_at":"2026-06-22T04:02:58.010121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bluejay Diagnostics Q3 net loss widens to $3.0M; cash $13.3M; FDA submission planned H1 2023","bullets":["Net loss for Q3 2022 was $3.0M ($0.15 per share) vs $1.2M ($0.11 per share) in Q3 2021.","Cash and cash equivalents at Sep 30, 2022: $13.3M, down from $19.0M at Dec 31, 2021; cash expected to fund operations for 12 months.","R&D expenses rose to $1.4M in Q3 2022 from $443k in Q3 2021 due to clinical program expansion and scale-up manufacturing.","No product sales in Q3; small non-recurring sale in Q2 2022 generated ~$250k revenue for nine months.","Company plans to submit De Novo application for Symphony IL-6 test with FDA in first half of 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-070134","json":"https://secwatch.observer/filing/0001213900-22-070134.json","markdown":"https://secwatch.observer/filing/0001213900-22-070134.md","text":"https://secwatch.observer/filing/0001213900-22-070134.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/0001213900-22-070134-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/ea168158-8k_bluejay.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:02:58.010121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"95d7ebbf621c324b53ed517bf30d7fb751deceb4","claim":"Bluejay Diagnostics, Inc. reported nine months ended September 30, 2022 results: net income $6.9 million, EPS $0.34 per share.","evidence_excerpt":"The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/0001213900-22-070134-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2022"},{"label":"Net income","value":"$6.9 million"},{"label":"EPS","value":"$0.34 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"afe06373f50522bce64e20df8b56cfdefe464f49","claim":"Bluejay Diagnostics, Inc. reported quarter ended September 30, 2022 results: net income $3.0 million, EPS $0.15 per share.","evidence_excerpt":"The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1704287/000121390022070134/0001213900-22-070134-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2022"},{"label":"Net income","value":"$3.0 million"},{"label":"EPS","value":"$0.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}